Advancing Atrial Fibrillation Therapy

Healium Medical develops no-contact guided ablation system for treatment of atrial fibrillation – the most common cardiac arrhythmia affecting more than 46.1 Million patients worldwide.

The company develops transcatheter ultrasound technology enabling rapid, no-contact circumferential

pulmonary vein isolation with real-time lesion monitoring. Our goal is to improve procedure efficacy

simplify procedure flow and shorten procedure time.

The company operates out of Yokneam, Israel, have full scale in-house R&D lab, employs multidisciplinary team of physicist, engineers & physicians and have pre-clinical data supporting the feasibility of its proprietary technology.

Description of Atrial Fibrillation:

Atrial fibrillation (AF or Afib for short) is the most

common cardiac arrhythmia or rhythm abnormality.

AF is an irregular and often rapid heart rate that may cause symptoms like heart palpitations, fatigue, and shortness of breath. AF occurs when the upper chambers of the heart (atria) beat rapidly and irregularly (fibrillate). This can cause blood to pool and form clots in an area of the heart called the left atrial appendage (LAA).

When a blood clot escapes from the LAA and travels

to another part of the body, it can cause a stroke.

These who have AF X5 times more likely to suffer a stroke than someone with a regular heartbeat.

Fortunately, AF may be treated with medication, cardioversion or a catheter ablation procedure. However, Despite the large number of advances in the field over the past two decades, AF remains a substantial cause of mortality and morbidity